Published in N Engl J Med on September 20, 2003
Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol (2007) 7.06
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol (2011) 3.51
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
miR-214 targets ATF4 to inhibit bone formation. Nat Med (2012) 3.01
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med (2012) 2.53
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest (2013) 2.08
Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest (2006) 1.92
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res (2008) 1.82
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab (2010) 1.77
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab (2011) 1.74
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest (2013) 1.70
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
Osteoporosis imaging: state of the art and advanced imaging. Radiology (2012) 1.58
Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford) (2008) 1.58
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (2015) 1.57
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res (2008) 1.55
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab (2012) 1.54
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res (2015) 1.50
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A (2008) 1.42
Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone (2007) 1.40
De novo autoimmune hepatitis associated with PTH(1-34) and PTH(1-84) administration for severe osteoporosis in a liver transplant patient. Osteoporos Int (2011) 1.39
beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res (2004) 1.39
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
Automated registration of hip and spine for longitudinal QCT studies: integration with 3D densitometric and structural analysis. Bone (2005) 1.29
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20
Reproducibility of results in preclinical studies: a perspective from the bone field. J Bone Miner Res (2014) 1.20
Trabecular bone structure analysis in the limited spatial resolution regime of in vivo MRI. Acad Radiol (2008) 1.19
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res (2008) 1.16
Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem (2008) 1.16
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int (2008) 1.14
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem (2010) 1.10
Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int (2012) 1.08
Identify fracture-critical regions inside the proximal femur using statistical parametric mapping. Bone (2008) 1.07
Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet (2008) 1.06
Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep (2013) 1.06
Treatment of osteoporosis in men. Bone (2012) 1.06
Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone (2011) 1.06
Locations of bone tissue at high risk of initial failure during compressive loading of the human vertebral body. Bone (2007) 1.06
Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporos Int (2004) 1.05
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int (2004) 1.05
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int (2010) 1.04
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab (2011) 1.03
Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab (2010) 1.03
An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. Endocrinology (2011) 1.01
Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev (2006) 1.01
Osteoporosis and skeletal fractures. HSS J (2006) 1.01
Use of osteoporosis medications in older nursing facility residents. J Am Med Dir Assoc (2007) 1.00
Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int (2005) 1.00
Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res (2010) 1.00
Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab (2009) 0.99
Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab (2014) 0.99
Current and future treatment options in osteoporosis. Eur J Clin Pharmacol (2011) 0.98
Automated 3D trabecular bone structure analysis of the proximal femur--prediction of biomechanical strength by CT and DXA. Osteoporos Int (2009) 0.98
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Parathyroid hormone plus alendronate--a combination that does not add up. N Engl J Med (2003) 0.98
Noninvasive imaging of bone microarchitecture. Ann N Y Acad Sci (2011) 0.98
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab (2005) 0.97
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int (2007) 0.97
An update on the assessment of osteoporosis using radiologic techniques. Eur Radiol (2006) 0.94
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med (2004) 0.94
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int (2007) 0.94
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A (2006) 0.94
Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab (2008) 0.94
Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol (2008) 0.93
Voxel-based modeling and quantification of the proximal femur using inter-subject registration of quantitative CT images. Bone (2007) 0.93
The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int (2011) 0.93
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res (2008) 0.92
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab (2012) 0.92
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord (2009) 0.91
Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. Osteoporos Int (2013) 0.91
Insights from the conduct of a device trial in older persons: low magnitude mechanical stimulation for musculoskeletal health. Clin Trials (2010) 0.90
Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. PLoS One (2013) 0.90
Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab (2014) 0.90
Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol (2004) 0.90
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int (2006) 0.90
Severe hypercalcemia due to teriparatide. Indian J Pharmacol (2012) 0.89
Teriparatide in the management of osteoporosis. Clin Interv Aging (2007) 0.89
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab (2005) 5.31
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA (2011) 4.83
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med (2008) 4.20
Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol (2006) 4.18
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest (2007) 3.76
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 3.50
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res (2007) 3.38
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33
Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res (2008) 3.33
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med (2011) 3.17
Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell (2009) 3.16
Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007) 3.15
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med (2011) 2.96
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med (2010) 2.60
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr (2006) 2.52
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 2.46
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res (2004) 2.46
Relationship of changes in physical activity and mortality among older women. JAMA (2003) 2.42
Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab (2005) 2.38
Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab (2004) 2.36
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. Arthritis Rheum (2004) 2.32
Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab (2009) 2.31
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom (2013) 2.29
Reduced renal function and sleep-disordered breathing in community-dwelling elderly men. Sleep Med (2008) 2.26
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom (2008) 2.21
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17
Diabetes and incidence of functional disability in older women. Diabetes Care (2002) 2.16
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res (2007) 2.15
The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab (2008) 2.12
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 2.10
Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology (2008) 2.09
Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab (2014) 2.08
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 2.04
High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. J Bone Miner Res (2010) 2.01
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A (2008) 1.98
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) (2010) 1.93
Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab (2006) 1.91
BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res (2006) 1.91
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res (2007) 1.88
Improving evaluation and treatment for osteoporosis following distal radial fractures. A prospective randomized intervention. J Bone Joint Surg Am (2008) 1.88
Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc (2004) 1.88
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 1.88
Differences in bone microarchitecture between postmenopausal Chinese-American and white women. J Bone Miner Res (2011) 1.86
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc (2004) 1.84
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res (2008) 1.82
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis Cartilage (2005) 1.82
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med (2005) 1.81
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81